Currently indicated for the treatment of CML and Philadelphia chromosome (+) ALL (acute lymphoblastic leukemia) after imatinib failure, dasatinib is a very potent TKI targeting Bcr-Abl, cKit, PDGFR-α and -β, and the Src family of kinases [9]. Here, SRC is linked to acute lymphoblastic leukemia.